Thymine nucleosides with anti-hepatitis B virus activity

a technology of hepatitis b virus and nucleosides, which is applied in the direction of biocide, sugar derivatives, pharmaceutical non-active ingredients, etc., can solve the problems of fulminant hepatitis, rapid progression, and jaundice in the abdomen, so as to prevent or retard the progression of clinical illness and effective anti-hbv treatment

Inactive Publication Date: 2005-12-15
OWENS HOWARD JR
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology describes methods for treating diseases associated with high levels of blood chloride concentration called Hepatic Chlamydia Syndrome ("HC"). By combining different drugs together it helps fight against harmful bacterial strains like Helvithromycini Atropic Acid Bacteroides). It suggests adding certain types of substances which could help reduce damage from viruses during this process.

Problems solved by technology

The technical problem addressed in this patent relates to providing novel compositions containing various components such as beta interference nucleus(CNS) necrosis factor receptor nuclear factors involved in pathogenesis related to hepatic tissue injury caused by bacteria called alpha hemolytic streptocytes (a type of white blood cells). These proteins play important roles during the process leading up to deaths due to system failure and drug resistance issues like chemoresistance.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Thymine nucleosides with anti-hepatitis B virus activity
  • Thymine nucleosides with anti-hepatitis B virus activity
  • Thymine nucleosides with anti-hepatitis B virus activity

Examples

Experimental program
Comparison scheme
Effect test

example = 1

EXAMPLE=1-(2-Fluoro-2,3-dideoxy-β-L-threo-pentofuranosyl)-5-fluorocytosine[2′-F-β-L β-L-FddC]

[0060]

[0061] Hitherto unknown 2′-F-β-L-FddC was synthesized in five steps from 1-(5-O-benzoyl-3-deoxy-β-L-erythro-pentofuranosyl)-5-fluorouracil 17 with an overall yield of 28% m.p. 209-210° C. (crystalized arom absolute ethanol); UV (Et OH) λmax 276 nm (ε, 9000), λmin 226nm (ε, 4000); 19F-NMR (DMSO-d6) δ ppm: −179.7 (m, F2′), −167.2 (dd, F5; JF.6=7.3 Hz, JF.1=1.5 Hz); 1H-NMR (DMSO-d6) δppm: 8.30 (d, 1H, H-6; J6,F=7.3 Hz), 7.8-7.5 (br s, 2H, NH2), 5.80 (d, 1H, H-1′ J1′,F=17.4 Hz), 5.34 (t, 1H, OH-5′; J=4.8 Hz), 5.10 (dd, 1H, H-2′; J2′,F=51.2 Hz; J2′,3′=3.4 Hz), 4.3 (m, 1H, H-4′), 3.8-3.6 (m, 2H, H-5′,5″), 2.2-2.0 (m, 2H, H-3′, H-3″); mass spectra (performed in: glycerol-thioglycerol, 1:1 υ / υ), FAB>O:248 (M+H)+, 130 (BH2)+; FAB−; [α]20D=−16.5 (−c 0.85, DMSO). Anal. Calc. for C9H11N3O3F2: C, 43.73; H, 9.49; N, 17.00; F, 15.37. Found: C, 43.56; H, 4.78; N, 16.75; F, 14.96.

II. Anti-HBV Activit

example 2

Toxicity of Compounds

[0072] The ability of the active compounds to inhibit the growth of virus in 2.2.15 cell cultures (HepG2 cells transformed with hepatitis virion) was evaluated. As illustrated in Table 1, no significant toxicity (greater than 50% depression of the dye untake levels observed in untreated cells) was observed for any of the test compounds at the concentrations 100 μM. The compounds were moderately toxic at 300 μM, however, all three compounds exhibited less toxicity at this concentration than β-D-ddC. It appears that the IC50 of β-L-ddC and β-L-FddC is approximately twice that of β-D-ddC.

[0073] Toxicity analyses were performed in 96-well flat bottomed tissue culture plates. Cells for the toxicity analyses were cultured and treated with test compounds with the same schedule as used for the antiviral evaluations. Each compound was tested at 4 concentrations, each in triplicate cultures. Uptake of neutral red dye was used to determine the relative level of toxicity. Th

example 3

Anti-Hepatitis B Virus Activity

[0074] The positive treatment control, β-D-2′,3′-dideoxycytosine [β-D-ddC], induced significant depressions of HBV DNA replication at the concentration used. Previous studies have indicated that at 9-12 μM of β-D-ddC, a 90% depression of HBV RI (relative to average levels in untreated cells) is typically observed in this assay system (Korba and Gerin, Antiviral Res. 19: 55-70, 1992). This is consistent with the data presented in Table 1.

[0075] The data presented in Table 1 indicates that all three test compounds ((β-L-FddC), (β-L-ddC), and β-D-FDOC)), were potent inhibitors of HBV replication, causing depression of HBV virion DNA and HBV RI to a degree comparable to, or greater than, that observed following treatment with β-D-ddC.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

A method for the treatment of a host, and in particular, a human, infected with hepatitis B virus (HBV) is provided that includes administering an effective amount of a β-L-thymine nucleotide, or a phosphate prodrug thereof, optionally in combination therapy with other drugs for the treatment of HBV.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner OWENS HOWARD JR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products